-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Diffuse large B-cell lymphoma (DLBCL) is a malignant tumor with diffuse growth of tumoric large B lymphocytes, diffuse nodular structure destruction or infiltration of large B lymphoid cells, with a high degree of heterogeneity and invasiveness, the R-CHOP regimen can only cure about 70% of patients, about 30-40% of patients are resistant or relapse, and the prognosis is poor
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) in adults, accounting for about (30-40%)
Currently, the WHO divides DBBCL into germination center B cell-like (GCB), activated B-cell-like (ABC) and type III DLBCL (Type 3 DLBCL
Recently reported in ESMO 2022, the use of machine learning for analysis analyzed 565 full-slice images (WSI) stained with hematoxylin/eosin in the dataset of the LYSA trial "GHEDI" (Deciphering the Genetic Heterogeneity of RITUXIMAB-era DLBCL
The results showed that the ROC AUC obtained by the DL model was 0.
This study demonstrates the predictive power of DL applied to WSI to predict DLBCL subtypes, and this predictive model can be used to improve pathologists' analytical capabilities, especially when IHC staining or FISH is not available
Related Stories:
NEJM: Landmark study: A more precise step in the classification of diffuse large B-cell lymphoma.
